Newsroom | 19887 results

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which inc...

DOVER, Del.--(BUSINESS WIRE)--n1.care launches an AI-powered clinical intelligence platform that transforms fragmented medical records into structured clinical insights....

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells. This Phase 1/2a, open-label, single-arm, uncontrolled, dose-escalation study (NCT06891885) is evaluating tw...

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced the launch of the duet mosaic family, which includes two new circulating cell-free DNA (cfDNA)-optimized multiomic sequencing workflows for liquid biopsy and translational research. duet +modC mosaic and duet 6-base mosaic enable academic researchers, translational scientists, and assay developers to generate genetic, epigenetic and fragmentomic information f...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health announces the winner of the 2026 Paul-Gallin Trailblazer Prize for Physician-Scientists....

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with limited treatment options, today announced the appointment of Mark Forman, M.D., Ph.D. as Chief Development Officer and Chief Medical Officer. Dr. Forman will oversee the company's clinical and development strategy as Acelot advances its pipeline of novel therapies targeting neurodegenerative diseases. "Mark joins Acelot at a pivotal time as we look...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

DALLAS--(BUSINESS WIRE)--Signature Biologics, a clinical-stage cell therapy company committed to rigorous clinical research and to the DMD community, today announced that the U.S. Food and Drug Administration (FDA) has allowed expanded enrollment in a clinical study of the company’s investigational umbilical cord–derived mesenchymal stem cell (UC-MSC) therapy in subjects with Duchenne muscular dystrophy (DMD). The study is conducted under an Investigational New Drug (IND) application held by it...

CORALVILLE, Iowa--(BUSINESS WIRE)--Research shows IDT's UNCOVERseq™ achieved the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods....